Effect of cryotherapy and povidone-iodine preparation on eradication of DNA corresponding to highly oncogenic HPV in women with lesions in the uterine cervix

In all 88 patients, 23-67 years of age (mean of 34.8 years) with abnormal cytology, lesions in the uterine cervix and presence of DNA corresponding to highly oncogenic HPV, two cycles of uterine cervix cryotherapy and local treatment with povidone-iodine resulted in eradication of the virus six months after detection of the virus.

HPV eradication; Infection; Cryotherapy; Povidone-iodine

[1] Sideri M., Cristoforoni P., Casadio C. Boveris, Igidbashian S., Schmitt M. et al.: “Distribution of human papillomavirus genotypes in invasive cervical cancer in Italy: A representative, single institution case series”. Vaccine, 2009, 27 (suppl. 1), A 30.

[2] Muñoz N., Bosch F.X., Castellsagué X., Diaz M., de Sanjose S., Hammouda D. et al.: “Against which human papillomavirus types shall we vaccinate and screen? The international perspective”. Int. J. Cancer, 2004, 111, 278.

[3] Baseman J.G., Koutsky L.A.: “The epidemiology of human papillomavirus infections”. J. Clin. Biol., 2005, 32 (suppl. 1), 16.

[4] Cuschieri K.S., Cubie H.A., Whitley M.W., Gilkison G., Arends M.J., Graham C. et al.: “Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study”. J. Clin. Pathol., 2005, 58, 946.

[5] Muñoz N., Castellsagué X., de González A.B, Gismann I.: “HPV in the etiology of human cancer”. Vaccine, 2006, 24 (suppl. 3), 1.

[6] Rodriguez A.C., Schiffman M., Harrero R., Hildesheim A., Bratti C., Sherman M.E. et al.: “Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection”. J. Natl. Cancer Inst., 2010, 102, 315.

[7] Zivadinovic R., Lilic G., Lilic V., Petric A., Filipovic S., Todorovska J. et al.: “Recurrence of cervical intraepithelial neoplasia with negative cone margins: risk factors”. J. BUON, 2011, 16, 498.

[8] Bansal N., Wright J.D., Cohen C.J., Herzog T.J.: “Natural history of established low grade cervical intraepithelial (CIN1) lesions”. Anticancer Res., 2008, 28, 1763.

[9] Schlecht N.F., Platt R.W., Durate-Franco E., Costa M.C., Sobrinho J.P., Prada J.C. et al.: “Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia”. J. Natl. Cancer Inst., 2003, 95, 1336.

[10] Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R., de Sanjose S., Bruni L. et al.: “Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia”. Vaccine, 2008, 26 (suppl. 10), K1.

[11] Moscicki A.B., Ma Y., Wibbelsman C., Darragh T.M., Powers A., Farhat S. et al.: “Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women”. Obstet. Gynecol., 2010, 116, 1373.

[12] Steben M., Durate-Franco E.: “Human papillomavirus infection: epidemiology and pathophysiology”. Gynecol. Oncol., 2007, 107 (suppl. 2), 2.

[13] Hellner K., Münger K.: “Human papillomaviruses as therapeutic targets in human cancer”. J. Clin. Oncol., 2011, 29, 1785.

[14] Harper C.M.: “Currently approved prophylactic HPV vaccines. Expert reviews”. Vaccines, 2009, 8, 1663.

[15] Martin D.M., O’Leary J.J.: “Histology of cervical intraepithelial neoplasia and the role of biomarkers”. Best Pract. Res. Clin. Obstet. Gynecol., 2011, 5, 605.

[16] Kim J.H., Bae S.N., Lee C.W., Song M.J., Lee S.J., Yoon J.H. et al.: A pilot study to investigate the treatment of cervical human papillomavirus infection with zinc-citrate compound (CIZAR)”. Gynecol. Oncol., 2011, 122, 303.

[17] He G., Wang Q., Zhou Y., Wu X., Wang L., Duru N. et al.: “YY1 is a novel potential therapeutic target for the treatment of HPV infection-induced cervical cancer by arsenic trioxide”. Int. J. Gynecol. Cancer, 2011, 21, 1097.

[18] Jones J., Saleem A., Rai N., Shylasree TS., Ashman S., Gregory K. et al.: “Human papillomavirus genotype testing combined with cytology as a “test of cure” post treatment: the importance of a persistent viral infection”. J. Clin. Virol., 2011, 52, 88.